Colorectal Cancer (CRC) Completed Phase 2 Trials for G17DT Immunogen (DB04914)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

IndicationStatusPhase
DBCOND0031867 (Colorectal Cancer (CRC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02518373
Effect of G17DT in Patients With Stage II/III Colorectal CancerTreatment
NCT02223078
Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.Treatment
NCT02181465
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.Treatment
NCT02118064
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal CarcinomaTreatment